IκK-16 decreases miRNA-155 expression and attenuates the human monocyte inflammatory response

PLoS One. 2017 Sep 14;12(9):e0183987. doi: 10.1371/journal.pone.0183987. eCollection 2017.

Abstract

Excessive inflammatory responses in the surgical patient may result in cellular hypo-responsiveness, which is associated with an increased risk of secondary infection and death. microRNAs (miRNAs), such as miR-155, are powerful regulators of inflammatory signalling pathways including nuclear factor κB (NFκB). Our objective was to determine the effect of IκK-16, a selective blocker of inhibitor of kappa-B kinase (IκK), on miRNA expression and the monocyte inflammatory response. In a model of endotoxin tolerance using primary human monocytes, impaired monocytes had decreased p65 expression with suppressed TNF-α and IL-10 production (P < 0.05). miR-155 and miR-138 levels were significantly upregulated at 17 h in the impaired monocyte (P < 0.05). Notably, IκK-16 decreased miR-155 expression with a corresponding dose-dependent decrease in TNF-α and IL-10 production (P < 0.05), and impaired monocyte function was associated with increased miR-155 and miR-138 expression. In the context of IκK-16 inhibition, miR-155 mimics increased TNF-α production, while miR-155 antagomirs decreased both TNF-α and IL-10 production. These data demonstrate that IκK-16 treatment attenuates the monocyte inflammatory response, which may occur through a miR-155-mediated mechanism, and that IκK-16 is a promising approach to limit the magnitude of an excessive innate inflammatory response to LPS.

MeSH terms

  • Female
  • Gene Expression Regulation / drug effects*
  • Humans
  • Inflammation / chemically induced
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Inflammation / pathology
  • Interleukin-10 / biosynthesis
  • Lipopolysaccharides / toxicity
  • Male
  • MicroRNAs / biosynthesis*
  • Monocytes / metabolism*
  • Monocytes / pathology
  • Protein Kinase Inhibitors / pharmacology*
  • Tumor Necrosis Factor-alpha / biosynthesis

Substances

  • IL10 protein, human
  • Lipopolysaccharides
  • MIRN155 microRNA, human
  • MicroRNAs
  • Protein Kinase Inhibitors
  • Tumor Necrosis Factor-alpha
  • Interleukin-10

Grants and funding

This publication was funded by the John W. Price and Barbara Thruston Atwood Price Trust, by the James and Emmeline Ferguson Research Fellowship Trust, by the Dizney Family Foundation, and by the Mary K. Oxley Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors would like to acknowledge the use of equipment from Jason Smith, MD PhD.